A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium,
fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy alone is
more effective then chemotherapy plus radiation therapy in treating rectal cancer.
PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to
chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.